Tech Center 1600 • Art Units: 1622
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19349768 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | Non-Final OA | Dermira, Inc. |
| 17772467 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | Non-Final OA | Dermira, Inc. |
| 17777247 | COMPOSITIONS FOR USE IN REDUCING INFLAMMATION | Non-Final OA | Evonik Operations GmbH |
| 18530612 | METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY | Non-Final OA | Massachusetts Institute of Technology |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | Non-Final OA | Bristol-Myers Squibb Company |
| 18599902 | Treatments for Diabetes Mellitus and Obesity | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18126547 | COMPOSITIONS FOR INHIBITING 3' REPAIR EXONUCLEASE 2 AND METHODS OF SCREENING FOR SUCH COMPOSITIONS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18003431 | HISTONE-ACETYLATION-MODULATING AGENTS FOR THE TREATMENT AND PREVENTION OF ORGAN INJURY | Non-Final OA | The Regents of the University of Michigan |
| 18663524 | Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization | Non-Final OA | BAYLOR COLLEGE OF MEDICINE |
| 18109406 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | Final Rejection | CASE WESTERN RESERVE UNIVERSITY |
| 17588104 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18167110 | AMINO ACID COMPOSITIONS AND USES THEREOF | Final Rejection | AMILYFE, LLC |
| 18973200 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | Non-Final OA | INCYTE CORPORATION |
| 18002814 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | Final Rejection | UNIVERSITE PARIS CITE |
| 18014045 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | Final Rejection | The USA, as represented by the Secretary, Department of Health and Human Services |
| 17290870 | SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF | Final Rejection | The Trustees of Princeton University |
| 17812126 | METHODS FOR REVERSING HEPATIC STEATOSIS | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18480145 | COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING POLY-y-GLUTAMIC ACID ISOLATED FROM BACILLUS AS ACTIVE INGREDIENT | Non-Final OA | PUKYONG NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION |
| 18638204 | NASAL COMPOSITION | Final Rejection | SATO PHARMACEUTICAL CO., LTD. |
| 16954105 | COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY | Non-Final OA | Actinium Pharmaceuticals, Inc. |
| 18213177 | COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDS AND ANTIEMETIC AGENTS | Non-Final OA | NURIX THERAPEUTICS, INC. |
| 18033345 | METABOLIC ACTIVATORS FOR ENHANCING SPERM CAPACITATION IN MAMMALS | Non-Final OA | UNIVERSIDADE DO PORTO |
| 18144230 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY COMPRISING MELATONIN AND PROSTAGLANDIN E2 FOR TREATING INTESTINAL EPITHELIAL INJURY AS AN ACTIVE INGREDIENT | Non-Final OA | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION |
| 18250236 | APPLICATION OF SESQUITERPENE LACTONE COMPOUND IN PREPARATION OF DRUGS FOR ALLEVIATING RADIOTHERAPY-INDUCED INJURIES | Non-Final OA | NANKAI UNIVERSITY |
| 18032320 | USE OF BENZODIAZEPINES TO INCREASE SENSITIVITY TO PSILOCYBIN FOLLOWING A CHRONIC SSRI REGIMEN | Non-Final OA | Compass Pathfinder Limited |
| 18373208 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER | Non-Final OA | CKP Therapeutics, Inc. |
| 18239740 | NATURAL DIETARY SUPPLEMENT FOR MENTAL HEALTH | Non-Final OA | Mind Pop LLC |
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | Non-Final OA | Ann And Robert H. Lurie Children's Hospital of Chicago |
| 18353525 | URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES | Final Rejection | UNIVERSIDAD DE SALAMANCA |
| 17741719 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN CORONAVIRUS DISEASE (COVID-19) | Final Rejection | PHARMAZZ, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy